Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc., following a class action lawsuit filed on behalf of investors who acquired RxSight securities between May 7, 2024, and July 8, 2025 [1][2]. Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery, utilizing the Company's Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the stall in LDD sales to adoption challenges over recent quarters [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified Class Period [1][2]. Company Overview - RxSight, Inc. is a medical technology company based in Aliso Viejo, CA, specializing in light adjustable intraocular lenses (LAL) used in cataract surgery, with its system involving the Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. The CEO attributed the sales stall to adoption challenges [4]. - Following this announcement, RxSight's shares dropped by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products, which contributed to its inability to meet previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter financial results on July 8, 2025, which showed significant declines in sales and revenue, RxSight lowered its full year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The lawsuit notes that RxSight's stock price fell nearly 38% following the announcement of disappointing financial results and guidance adjustments [5].

Group 1 - RxSight, Inc. is under investigation for potential securities fraud claims following significant declines in sales and revenue [1][2] - The company reported a 37% drop in share price, closing at $7.95 per share after disclosing adoption challenges affecting LDD sales and LAL utilization [2] - Investors who acquired RxSight stock between November 7, 2024, and July 8, 2025, may seek lead plaintiff status in the ongoing litigation [3] Group 2 - RxSight specializes in medical technology, specifically developing light adjustable intraocular lenses (LAL) for cataract surgery [1] - The company's Light Delivery Device (LDD) is a key component of its RxSight system [1]

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products, which contributed to the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of the lowered guidance and the challenges faced by RxSight led to a nearly 38% drop in the company's stock price [5].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products, which contributed to the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of the poor financial results led to a nearly 38% drop in the price of RxSight stock [5].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified Class Period [1][2]. Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery [2]. Legal Allegations - The lawsuit alleges that RxSight failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the decline to adoption challenges [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of the financial results led to a nearly 38% drop in the price of RxSight stock [5].

Core Viewpoint - A class action has been filed against RxSight, Inc. for allegedly misleading investors about product demand and financial performance during a specified period [1][2]. Group 1: Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the U.S. [1] - The primary product of RxSight is the RxSight system, which includes the LAL and the Light Delivery Device (LDD) [1]. Group 2: Allegations and Financial Performance - The class action alleges that RxSight failed to disclose adoption challenges and structural issues leading to declines in sales and utilization of its products [2]. - The complaint claims that RxSight overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, and lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [3]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025 [3].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines following the disclosure of poor financial results [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of poor financial results led to a nearly 38% drop in the price of RxSight's stock [5].